AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) shares saw unusually-high trading volume on Friday . Approximately 8,096,829 shares traded hands during mid-day trading, an increase of 3% from the previous session’s volume of 7,893,260 shares.The stock last traded at $3.89 and had previously closed at $3.99.
AVEO has been the topic of a number of research reports. FBR & Co reissued a “buy” rating and issued a $3.00 price objective on shares of AVEO Pharmaceuticals in a report on Friday, June 30th. Piper Jaffray Companies set a $2.00 price objective on AVEO Pharmaceuticals and gave the company a “buy” rating in a report on Saturday, June 24th. Zacks Investment Research raised AVEO Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 price objective on the stock in a report on Monday, July 24th. ValuEngine raised AVEO Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, June 24th. Finally, BidaskClub raised AVEO Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, August 16th. One analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $3.42.
The firm’s 50-day moving average price is $3.00 and its 200 day moving average price is $1.51. The stock’s market cap is $449.57 million.
A number of institutional investors and hedge funds have recently bought and sold shares of AVEO. Fore Research & Management LP purchased a new stake in AVEO Pharmaceuticals during the 2nd quarter valued at approximately $111,000. Paloma Partners Management Co purchased a new stake in AVEO Pharmaceuticals during the 1st quarter valued at approximately $184,000. Cannell Peter B & Co. Inc. raised its stake in AVEO Pharmaceuticals by 22.9% during the 2nd quarter. Cannell Peter B & Co. Inc. now owns 109,875 shares of the biopharmaceutical company’s stock valued at $244,000 after acquiring an additional 20,500 shares during the last quarter. Clear Harbor Asset Management LLC purchased a new stake in AVEO Pharmaceuticals during the 2nd quarter valued at approximately $289,000. Finally, UBS Oconnor LLC purchased a new stake in AVEO Pharmaceuticals during the 1st quarter valued at approximately $291,000. 53.76% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “AVEO Pharmaceuticals, Inc. (AVEO) Sees Large Volume Increase” was published by BBNS and is the property of of BBNS. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://baseballnewssource.com/markets/aveo-pharmaceuticals-inc-aveo-sees-large-volume-increase/1605426.html.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
Receive News & Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.